The commitment to improve lives starts at the top.

Robert E. Dudley, Ph.D.

President and Chief Executive Officer

Robert E. Dudley, Ph.D., serves as a member of the board of directors for Clarus Therapeutics. Having devoted over 30 years to developing products that revolutionize healthcare for men, Dr. Dudley is a prominent voice in hypogonadism and men’s health. He is the co-inventor of multiple formulations of testosterone replacement therapies, including leading the discovery, development, regulatory approval, and launch of AndroGel 1%, the first testosterone gel product, which became the market leader.

Driven by a mission to help men overcome the symptoms of hypogonadism, Dr. Dudley founded Clarus Therapeutics in 2004 and has served as the Company’s President and Chief Executive Officer since its inception, also serving as Chairman of the Board until it became a publicly traded company in August 2021. Prior to founding Clarus Therapeutics, Dr. Dudley served as the President, Chief Executive Officer and Director of Anagen Therapeutics. He also has held senior executive positions at Unimed Pharmaceuticals (formerly Nasdaq:UMED), including President and Chief Executive Officer prior to and after Unimed’s acquisition by Solvay Pharmaceuticals.

Patients deserve a choice and an opportunity to have access to medicines that can improve the quality of their lives.

Ric Peterson

Chief Financial Officer

Ric Peterson has deep financial expertise and forward-thinking business leadership, with extensive experience in capital markets having completed numerous successful private and public financings (IPOs). He joined Clarus Therapeutics in February 2021 as Chief Financial Officer, bringing 25 years of experience in the pharmaceutical industry and long-standing relationships within the financial community. Prior to joining Clarus Therapeutics, Mr. Peterson served as Chief Financial Officer for several clinical-stage biopharmaceutical companies, including Sienna Biopharmaceuticals, Dermavant Sciences, Inc. and Novan, Inc. He was also Chief Financial Officer of Medicis Pharmaceutical Corporation, a commercial pharmaceutical company.

It’s an exciting time to join the Clarus team and help them grow Clarus into a profitable, multi-product pharmaceutical company.

Steven A. Bourne

Chief Administrative Officer

Steve Bourne has a passion for working with innovative, early-stage life sciences companies. He joined Clarus Therapeutics in February 2004 and currently serves as Chief Administrative Officer. His career has spanned more than three decades, amassing deep administration and financial leadership expertise for specialty pharmaceutical, biotech and medical device companies. Prior to joining Clarus Therapeutics, Mr. Bourne served as Chief Financial Officer, Secretary and Treasurer at Anagen Therapeutics and Treasurer, Secretary and Controller at Aksys, a publicly traded medical device company.

For me, it’s personal. Working in men’s health is gratifying for me but I also do it for my family and my loved ones.

Frank Jaeger

Chief Commercial Officer

Mr. Jaeger joined Clarus Therapeutics in 2019 as Chief Commercial Officer with over 20 years of progressively increasing responsibility in the biopharmaceutical industry. With significant pre-launch, launch, and in-market experience, Mr. Jaeger is committed to ensuring that innovative treatments are developed and promoted through the lens of the customer. His broad leadership and management experience spans across R&D, Medical Affairs, Business Development, and most notably throughout Commercial Operations. Prior to joining Clarus, he spent over 10 years at Abbott/AbbVie and was responsible for the Men’s Health division growing it from $600 MM to over $1.3 BN. Previously, Mr. Jaeger was at Solvay Pharmaceuticals in roles of increasing responsibility within the Neuroscience, Gastroenterology, and Women’s Health franchises. Mr. Jaeger received a B.A. and M.A. in clinical psychology from University of Illinois, Chicago and an M.B.A. from Lake Forest Graduate School of Management.

It’s really been rewarding to see men suddenly having conversations with their physicians and realizing that they can be helped.

It’s really been rewarding to see men suddenly having conversations with their physicians and realizing that they can be helped.

Jay Newmark, MD

Chief Medical Officer

With extensive experience in both private urology practice and commercial product development, Jay Newmark was already a leading voice in men’s health when he joined Clarus Therapeutics in December 2019 as Chief Medical Officer. Following 16 years as a urologist in private practice, he worked to develop advanced detection technologies for prostate cancer as Senior Director of Medical Affairs at Genomic Health and OPKO Health. He has worked closely with clinical development organizations and academic researchers to design clinical trial protocols and co-author publications on topics in oncology and urology.

It’s fulfilling to be part of an organization committed to developing innovative treatments that make a real difference.

Steven A. Bourne, CPA

Chief Financial Officer, Secretary and Treasurer

Steven A. Bourne, CPA, is a finance and accounting professional with a passion for working with innovative, early-stage life science companies. He joined Clarus Therapeutics in February 2004 and currently serves as Chief Financial Officer, Secretary and Treasurer. His career has spanned more than two and a half decades, amassing deep financial leadership expertise for specialty pharmaceutical, biotech and medical device companies. Prior to Clarus Therapeutics, he served as Chief Financial Officer, Secretary and Treasurer at Anagen Therapeutics and Treasurer, Secretary and Controller at Aksys, a public medical device company.

For me, it’s personal. I do this not only for myself, but for my family and my loved ones.

James Holloway

Senior Vice President, Manufacturing and Supply

James Holloway joined Clarus Therapeutics in October 2019 as Vice President, Manufacturing and Supply with extensive experience in pharmaceutical manufacturing operations. His background includes roles of increasing responsibility at DSM Pharmaceuticals, Cardinal Health, Pfizer and Boehringer Ingelheim. Prior to Clarus Therapeutics, he led the research and development project management office of the Infection Prevention franchise of CareFusion (now BD Medical), where he increased revenue and improved on-time delivery. Mr. Holloway has launched more than 55 drugs and biologic products.

We strive to make a difference in men’s health by focusing on developing a high-quality, safe, and effective TRT product.

Creating access to medicines for patients is one of the most important jobs in pharma and is the reason for my passion in this industry.

Rozita Passarella

Vice President, Marketing

Rozita Passarella has over a decade of experience as a sales and marketing leader in biopharmaceuticals. Before joining Clarus, she was instrumental in helping AndroGel gain blockbuster status during her tenure. Ms. Passarella has broad-based experience in a variety of disease states, including cardiology, immunology, metabolic, and women’s health. She has led marketing efforts to launch new formulations as well as new products within large integrated delivery networks (IDNs) and group practices.

Clarus is focused and relentless in improving patients’ lives by addressing unmet needs, whether that be in delivering a new mode of administration or a therapy for an orphan condition that is without treatment or therapy.

LaTonya Wright

Vice President, Sales

LaTonya Wright is a proven leader whose teams consistently exceed ambitious sales targets. She joined Clarus Therapeutics in October 2019 as Vice President, Sales with more than 20 years of healthcare experience gained through roles at Amgen, Abbott and AbbVie. Under her leadership as Regional Sales Director at AbbVie, her team won national awards for sales and performance. Previously, she launched another TRT treatment with an innovative go-to-market model. At Clarus Therapeutics, Ms. Wright is in charge of building and leading the sales organization by developing sales, market access and operational strategies.

Our goal—every day—is to raise awareness of men’s health and to spark the conversations that will activate men to be proactive in their healthcare.

Gregory Fox

Vice President, Market Access

Gregory Fox, a 23-year veteran of the pharmaceutical industry, has been a contributor to many sides of the business including sales, sales leadership, sales training, market access and trade. He joined Clarus Therapeutics in March 2021 as Vice President of Market Access. Prior to Clarus Therapeutics, Mr. Fox held leadership roles at SK Life Science as Executive Director of Market Access and Ironshore Pharmaceuticals and Development as Vice President of Corporate Accounts. Mr. Fox also spent the first 19 years of his pharmaceutical career with UCB and has successfully led market access teams of varying sizes and scopes for the last 11 years.

Creating access to medicines for patients is one of the most important jobs in pharma and is the reason for my passion in this industry.

Steve Stark

Vice President, Commercial Analytics and Operations

Steve Stark brings over 20 years of experience within commercial analytics and operations in the biopharmaceutical industry. Prior to joining Clarus Therapeutics, Mr. Stark held strategic and leadership roles at ZS Associates and Abbott/AbbVie. Most recently, he was Senior Director of Business Insights at Lundbeck. In that role, he led market research, brand and payer analytics, forecasting and commercial assessment in delivering integrated insights to inform brand decisions.

At Clarus Therapeutics, we are committed to bringing innovative products to the market to improve men’s health. I’m proud to be part of an organization with such a meaningful mission.

Kara Stancell

Vice President, Investor Relations and Corporate Communications

Kara J. Stancell is a public relations, investor relations and corporate communications veteran with more than 20 years of professional healthcare, pharmaceutical and biotech communications and consulting experience. Most recently, Ms. Stancell served as vice president, investor relations and corporate communications at Dermavant Sciences, a clinical-stage biopharmaceutical company. Prior to that, she spent 10 years as corporate spokesperson for Medicis Pharmaceutical Corporation, leaving as vice president, investor and public relations and corporate communications when the company was acquired in 2012.

It’s an honor to join such an experienced and dedicated team during this exciting time of growth in Clarus’ history.

Kimberly Murphy

Chair

Kim Murphy chairs the board of directors for Clarus Therapeutics. Ms. Murphy has more than 25 years of experience at leading pharmaceutical companies, including Novartis, Merck, and GlaxoSmithKline. She also has board and advisory experience, serving on the board of directors for Oragenics and Blue Water Vaccines, serving as the GSK Representative to the Biotechnology Industry Organization’s Biodefense Advisory Council, and serving on the St. Joseph’s University Pharmaceutical & Healthcare Marketing MBA Program’s Advisory Board. Prior to chairing the board for Clarus Therapeutics, Ms. Murphy served as a director for Blue Water Acquisition Corp.

John Amory

Director

John A. Amory, M.D., M.P.H, M.Sc., serves as a member of the board of directors for Clarus Therapeutics. Since July 2011, Dr. Amory has served as a Professor of Medicine at the University of Washington in Seattle and as a member of the faculty of the University of Washington since 1997. During his career, he has published more than 154 peer-reviewed papers in the field of male reproduction. His areas of research include male infertility, testosterone deficiency, and the development of novel male contraceptives. Dr. Amory earned his M.D. from the University of California — San Francisco and both his M.P.H. and M.Sc. (pharmaceutics) from the University of Washington.

Elizabeth A. Cermak

Director and Chair, Nominating and Corporate Governance Committee

Elizabeth Cermak serves as a member of the board of directors and as chair of the nominating and corporate governance committee for Clarus Therapeutics. Ms. Cermak has more than 30 years of experience in the pharmaceutical and life sciences industries. She is the former Chief Commercial Officer and Executive Vice President of POZEN. She also held senior leadership roles during her 25 years at Johnson & Johnson. Ms. Cermak currently serves on the board of directors for Moleculin Biotech and QUE Oncology and has served on the board of directors for SteadyMed Therapeutics as well as Clarus before it became a publicly traded company.

Robert E. Dudley

Director, Founder, President and Chief Executive Officer, Clarus Therapeutics

Robert E. Dudley, Ph.D., serves as a member of the board of directors for Clarus Therapeutics. Having devoted over 30 years to developing products that revolutionize healthcare for men, Dr. Dudley is a prominent voice in hypogonadism and men’s health. He is the co-inventor of multiple formulations of testosterone replacement therapies, including leading the discovery, development, regulatory approval, and launch of AndroGel 1%, the first testosterone gel product, which became the market leader.

Driven by a mission to help men overcome the symptoms of hypogonadism, Dr. Dudley founded Clarus Therapeutics in 2004 and has served as the Company’s President and Chief Executive Officer since its inception, also serving as Chairman of the Board until it became a publicly traded company in August 2021. Prior to founding Clarus Therapeutics, Dr. Dudley served as the President, Chief Executive Officer and Director of Anagen Therapeutics. He also has held senior executive positions at Unimed Pharmaceuticals (formerly Nasdaq:UMED), including President and Chief Executive Officer prior to and after Unimed’s acquisition by Solvay Pharmaceuticals.

Joseph Hernandez

Director

Joseph Hernandez serves as a member of the board of directors for Clarus Therapeutics. Mr. Hernandez has over 25 years of experience in the healthcare field backed by a strong educational foundation in biology, medicine, molecular genetics, microbiology, epidemiology, marketing, and finance. He is an entrepreneurial leader with a background in company creation, early-stage technology development, and private and public market financing who built his career at Merck and Digene. He has successfully founded or led eight entrepreneurial companies in cutting edge areas of healthcare and pharmaceuticals, including Noachis Terra, Blue Water Vaccines, Sydys Corp., Ember Therapeutics, Microlin Bio, and Innovative Biosensors. Prior to serving as a director for Clarus Therapeutics, Mr. Hernandez served as Chairman and Chief Executive Officer for Blue Water Acquisition Corp.

Mark A. Prygocki, Sr.

Director and Chair, Audit Committee

Mark Prygocki serves as a member of the board of directors and as chair of the audit committee for Clarus Therapeutics. With more than 25 years of leadership and consulting experience in the pharmaceutical, biotechnology, and retail industries, Mr. Prygocki specializes in corporate strategy and operational efficiency. He is the former Chief Executive Officer, President, and Director of Illustris Pharmaceuticals and past President of Medicis Pharmaceutical Corp. He also has held roles at Citigroup and Ernst & Young. Mr. Prygocki currently serves on the board of directors and as chairman of the audit committee for Verrica Pharmaceuticals and on the board of directors for Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs. He also served on the board of directors of Clarus before it became a publicly traded company. Mr. Prygocki is certified by the American Institute of Certified Public Accountants.

Alex Zisson

Director and Chair, Compensation Committee

Alex Zisson serves as a member of the board of directors and as chair of the compensation committee for Clarus Therapeutics. Mr. Zisson has more than 25 years of experience as a healthcare strategist, researcher, and venture investor in the pharmaceutical, biotechnology, and life sciences industries, serving in leading roles at H.I.G. BioHealth Partners, Thomas, McNerney & Partners, Hambrecht & Quist, Chase H&Q, and JPMorgan. He also serves on the board of directors of a number of private companies, including Leiters Pharmacy, Neurana Pharmaceuticals, Taconic Biosciences, and BioVectra, and served on the board of directors of Clarus before it became a publicly traded company.